menu
    • menu
    [{"orgOrder":0,"company":"Eric B. Suhler","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Eric B. Suhler","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eric B. Suhler \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Eric B. Suhler \/ Genentech"},{"orgOrder":0,"company":"Intelligem Therapeutics Australia Pty Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IG3018","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Intelligem Therapeutics Australia Pty Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intelligem Therapeutics Australia Pty Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Intelligem Therapeutics Australia Pty Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Urica Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dontinurad","moa":"URAT1","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Urica Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Urica Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Urica Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ALN-XDH","moa":"Xanthine dehydrogenase\/oxidase messenger RNA (XDH mRNA)","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adaptive Phage Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crystalys Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Crystalys Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad,Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $205.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Novo-Backed Crystalys Debuts With $205M to Tackle Gout

                            Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.

                            Product Name : FYU-981

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 30, 2025

                            Lead Product(s) : Dotinurad,Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $205.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanton Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Shanton Pharma

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAP-001

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function

                            Details : SAP-001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 11, 2024

                            Lead Product(s) : SAP-001

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Intelligem Therapeutics Australia Pty Ltd.

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Intelligem Therapeutics Australia Pty Ltd.

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IG3018

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease

                            Details : IG3018 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 15, 2024

                            Lead Product(s) : IG3018

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Urica Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Urica Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dontinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

                            Details : Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 28, 2023

                            Lead Product(s) : Dontinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sunshine Guojian Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Sunshine Guojian Pharmaceutical

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Anti-IL-1 Humanized Monoclonal Antibody

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participan...

                            Details : Recombinant Anti-IL-1 Humanized Monoclonal Antibody is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 20, 2022

                            Lead Product(s) : Recombinant Anti-IL-1 Humanized Monoclonal Antibody

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            GeneScience Pharmaceuticals Co Ltd

                            China arrow
                            OTS 2025
                            Not Confirmed

                            GeneScience Pharmaceuticals Co Ltd

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Genakumab

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Study of Genakumab for Injection in Patients With Acute Gout

                            Details : Genakumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 14, 2022

                            Lead Product(s) : Genakumab

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Adaptive Phage Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Adaptive Phage Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections

                            Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthritis, Infectious.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALN-XDH

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout

                            Details : ALN-XDH is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 25, 2022

                            Lead Product(s) : ALN-XDH

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Adaptive Phage Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Adaptive Phage Therapeutics

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Mayo Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bacteriophage Therapy in Patients With Prosthetic Joint Infections

                            Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthritis, Infectious.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 08, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Mayo Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            InventisBio

                            China arrow
                            OTS 2025
                            Not Confirmed

                            InventisBio

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : D-0120

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            D-0120 Safety and PK/PD Study in China

                            Details : D-0120 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 23, 2019

                            Lead Product(s) : D-0120

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth